Entera Bio Ltd. (ENTX)

Over the past six months, Entera Bio experienced several stock-related events. The FDA provided alignment on the EB613 Phase 3 endpoint, and the protocol was submitted. Positive preclinical data for long-acting PTH analogs was announced. The company reported a net loss of $11.4 million for 2025. Board members purchased company stock. Geno J. Germano was appointed as Chairman of the Board. Analyst downgrades and a stock price decline of 36.57% were noted.

As a clinical-stage biopharmaceutical company focused on research and development, Entera Bio Ltd. does not experience discernible demand seasonality for its products or services.

Entera Bio Ltd. is a clinical-stage biopharmaceutical company focused on developing oral peptide and protein replacement therapies. The company's core strategy involves its N-Tab™ oral peptide platform, which aims to convert injectable biologic drugs into oral tablet formats. Its major product candidates include EB613 for osteoporosis, EB612 for hypoparathyroidism, oral Oxyntomodulin for obesity and metabolic disorders, and a GLP-2 peptide tablet for rare malabsorption conditions.

Entera Bio Ltd. is headquartered in Jerusalem, Israel. The company's shares are listed on the Nasdaq Capital Market in the United States and on the Deutsche Boerse AG in Germany.

Entera Bio's brand reputation, as assessed by MarketBeat, scored higher than 68% of companies in the medical sector. The company has a consensus rating of "Hold" from analysts, with an average rating score of 2.00. Analyst downgrades and positive clinical updates have affected its reputation.

Entera Bio Ltd. has both institutional and insider ownership. Institutional investors hold between 14.11% and 20.34% of the company's stock, with major holders including Knoll Capital Management, Point72 Asset Management, and others. Insider ownership ranges from approximately 4.43% to 10.38%, with recent purchases by the CEO.